Table 3.
Safety and efficacy outcomes in univariate analysis
| Parameter | No OAC | VKA | p value | NOAC | p value | Included patients, n (%) |
|---|---|---|---|---|---|---|
| Reperfusion rate (mTICI 2b–3), n (%) | 4032 (84.3) | 404 (85.6) | 0.93 | 701 (85.3) | 1 | 6077 (98.4) |
| ICH 24 h, n (%) | 712 (14.6) | 60 (12.5) | 0.44 | 97 (11.7) | 0.06 | 6173 (100) |
| mRS 0–2 on d90, n (%) | 1672 (39.5) | 116 (27.8) | < 0.005 | 197 (27.9) | < 0.005 | 5353 (86.7) |
| Good outcome (mRS 0–2 or back to baseline) on d90, n (%) | 1744 (41.4) | 130 (31.3) | < 0.005 | 218 (31.1) | < 0.005 | 5332 (86.4%) |
OAC oral anticoagulation, VKA vitamin K antagonist, NOAC non-vitamin K antagonist oral anticoagulation anticoagulant, mTICI modified thrombolysis in cerebral infarction, ICH intracranial hemorrhage, mRS modified Rankin scale